CSL Behring recently joined with other plasma medicine companies to announce a U.S.-funded clinical trial of a plasma-based hyperimmune globulin to treat severe symptoms of COVID-19.
Watch the video to hear from members of the CoVIg-19 Plasma Alliance about this important milestone for what could be one of the first approved treatments for hospitalized patients fighting the novel coronavirus. An arm of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases, recently announced the start of a clinical trial that will enroll 500 adult patients at 58 sites in the United States.
The hyperimmune is a shelf-stable product that contains a dependable level of concentrated COVID-19 antibodies. The clinical trial wouldn’t be possible without the patients who recovered from the virus and donated their plasma, which contains antibodies, to help. The clinical trial will assess the potential product’s safety, tolerability and efficacy.
Plasma continues to be needed for potential COVID-19 treatments and medicines that treat people who have primary immune deficiencies and other rare diseases.
